Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
•
Mesothelioma
Has the MARS data for mesothelioma changed whether you would recommend surgery for these patients?
Related Questions
How would you treat patients with limited-stage small cell lung cancer who have short term contraindications for systemic chemotherapy?
What is your approach for an RA patient with lung cancer who is starting immunotherapy?
Would a BRAF V600E mutation affect your decision to give adjuvant therapy in a patient with lung cancer?
In cases where EGFR NSCLC has transformed into small-cell lung cancer after treatment with Osimertinib, and with no CNS involvement, is it advisable to continue osimertinib alongside chemotherapy?
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
Is there a role for surgical debulking for patients with stage IV lung sarcomatoid carcinoma?
In what situations would immunotherapy alone be appropriate for non-metastatic NSCLC?
What treatment would you recommend for a patient with non-mutated Stage III lung squamous cell carcinoma with relapse following neoadjuvant chemoimmunotherapy, surgery, and during adjuvant immunotherapy?
What adjuvant therapy, if any, would you offer for a young fit patient with stage IB lung adenocarcinoma harboring an EGFR A763_Y764insFQEA who received no prior therapy?
What is the preferred concurrent chemotherapy regimen for limited stage small cell lung cancer with severe reaction to etoposide?
